Business Context and Reporting Period
Company: Acadia Healthcare Company, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 30, 2020
Event: Entry into a Material Definitive Agreement regarding the sale of the Company's U.K. business operations (Priory Group).
Key Financial Metrics and Transaction Details
- Transaction Type: Sale of 100% of securities of AHC-WW Jersey Limited (U.K. operations) to RemedcoUK Limited.
- Purchase Price: Approximately £1,078 million.
- Expected Net Proceeds: Approximately $1,350 million (based on current GBP/USD exchange rate, net of transaction costs and foreign currency hedging liabilities).
- Payment Terms: Full payment in cash on the closing date.
- Use of Proceeds: Pay down debt and other corporate purposes.
- Expected Closing Date: January 19, 2021.
Material Changes and Transaction Structure
The Company entered into a Put and Call Option Deed with the Purchaser. Both parties hold the right to exercise the option to finalize the sale during a specific "Option Period" (January 7, 2021, to January 8, 2021). If either option is exercised, a Share Purchase Agreement (SPA) will automatically come into effect, mandating the sale of the U.K. business. This represents a significant divestiture of the Company's international operations.
Outlook, Risks, and Management Commentary
- Management Expectation: The Company anticipates the sale will close in January 2021.
- Forward-Looking Statements: The filing contains forward-looking statements regarding the timing, purchase price, net proceeds, and benefits of the transaction.
- Risks and Contingencies: Actual results may differ materially due to uncertainties regarding the completion of the SPA, the final purchase price, and the Company's ability to achieve intended benefits. The transaction is subject to customary warranties and covenants.
- Regulatory Disclosure: A press release was issued on December 30, 2020, and is attached as Exhibit 99.1.
Key Facts for Investor Verification
- Verify the final closing date and whether the transaction completes as scheduled in January 2021.
- Confirm the actual net proceeds received after accounting for final transaction costs and currency exchange rates at closing.
- Monitor the Company's subsequent filings for the impact of the debt paydown on the balance sheet.
- Review the full Share Purchase Agreement (SPA) once filed as an exhibit to the Annual Report on Form 10-K for detailed covenants and conditions.